

Special Issue

Non-Melanoma Skin Cancer: Advances Towards Prevention and Personalized Medicine in Clinical Practice

Message from the Guest Editors

Non-melanoma skin cancer (NMSC) is the most frequent tumor in humans. NMSC exhibits a special behavior, not only emerging through the classical route of accumulated mutation, but also via alternative pathways. We are pleased to invite you to participate in this Special Issue focused on NMSC prevention and treatment based on translational strategies with real-practice clinical application. This Special Issue is open and practical, with the purpose of linking clinical practice with basic science. Clinicians and researchers are encouraged to share their detailed experience, including negative or null results. This Special Issue aims to:

- Expand the knowledge of novel clinical strategies for NMSC treatment and prevention.
- Share new targeted therapies in NMSC with the scientific community.
- Be a connector between dermatologists and basic research.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Guest Editors

Dr. Montserrat Fernández-Guarino

Dermatology Service, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Carretera de Colmenar Km 9, 28034 Madrid, Spain

Dr. Stefano Bacci

Research Unit of Histology and Embryology, Department of Biology, University of Florence, Florence, Italy

Deadline for manuscript submissions

closed (31 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/150726

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)